Low-Dose Metformin as a Monotherapy Does Not Reduce Non-Small-Cell Lung Cancer Tumor Burden in Mice

Non-small-cell lung cancer (NSCLC) makes up 80–85% of lung cancer diagnoses. Lung cancer patients undergo surgical procedures, chemotherapy, and/or radiation. Chemotherapy and radiation can induce deleterious systemic side effects, particularly within skeletal muscle. To determine whether metformin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nicole L. Stott Bond, Didier Dréau, Ian Marriott, Jeanette M. Bennett, Michael J. Turner, Susan T. Arthur, Joseph S. Marino
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	Lewis lung model lung cancer skeletal muscle cachexia Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/5b63c08f901940bfac88d7f742fc1f04
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5b63c08f901940bfac88d7f742fc1f04
record_format	dspace
spelling	oai:doaj.org-article:5b63c08f901940bfac88d7f742fc1f042021-11-25T16:50:49ZLow-Dose Metformin as a Monotherapy Does Not Reduce Non-Small-Cell Lung Cancer Tumor Burden in Mice10.3390/biomedicines91116852227-9059https://doaj.org/article/5b63c08f901940bfac88d7f742fc1f042021-11-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1685https://doaj.org/toc/2227-9059Non-small-cell lung cancer (NSCLC) makes up 80–85% of lung cancer diagnoses. Lung cancer patients undergo surgical procedures, chemotherapy, and/or radiation. Chemotherapy and radiation can induce deleterious systemic side effects, particularly within skeletal muscle. To determine whether metformin reduces NSCLC tumor burden while maintaining skeletal muscle health, C57BL/6J mice were injected with Lewis lung cancer (LL/2), containing a bioluminescent reporter for in vivo tracking, into the left lung. Control and metformin (250 mg/kg) groups received treatments twice weekly. Skeletal muscle was analyzed for changes in genes and proteins related to inflammation, muscle mass, and metabolism. The LL/2 model effectively mimics lung cancer growth and tumor burden. The in vivo data indicate that metformin as administered was not associated with significant improvement in tumor burden in this immunocompetent NSCLC model. Additionally, metformin was not associated with significant changes in key tumor cell division and inflammation markers, or improved skeletal muscle health. Metformin treatment, while exhibiting anti-neoplastic characteristics in many cancers, appears not to be an appropriate monotherapy for NSCLC tumor growth in vivo. Future studies should pursue co-treatment modalities, with metformin as a potentially supportive drug rather than a monotherapy to mitigate cancer progression.Nicole L. Stott BondDidier DréauIan MarriottJeanette M. BennettMichael J. TurnerSusan T. ArthurJoseph S. MarinoMDPI AGarticleLewis lung modellung cancerskeletal musclecachexiaBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1685, p 1685 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Lewis lung model lung cancer skeletal muscle cachexia Biology (General) QH301-705.5
spellingShingle	Lewis lung model lung cancer skeletal muscle cachexia Biology (General) QH301-705.5 Nicole L. Stott Bond Didier Dréau Ian Marriott Jeanette M. Bennett Michael J. Turner Susan T. Arthur Joseph S. Marino Low-Dose Metformin as a Monotherapy Does Not Reduce Non-Small-Cell Lung Cancer Tumor Burden in Mice
description	Non-small-cell lung cancer (NSCLC) makes up 80–85% of lung cancer diagnoses. Lung cancer patients undergo surgical procedures, chemotherapy, and/or radiation. Chemotherapy and radiation can induce deleterious systemic side effects, particularly within skeletal muscle. To determine whether metformin reduces NSCLC tumor burden while maintaining skeletal muscle health, C57BL/6J mice were injected with Lewis lung cancer (LL/2), containing a bioluminescent reporter for in vivo tracking, into the left lung. Control and metformin (250 mg/kg) groups received treatments twice weekly. Skeletal muscle was analyzed for changes in genes and proteins related to inflammation, muscle mass, and metabolism. The LL/2 model effectively mimics lung cancer growth and tumor burden. The in vivo data indicate that metformin as administered was not associated with significant improvement in tumor burden in this immunocompetent NSCLC model. Additionally, metformin was not associated with significant changes in key tumor cell division and inflammation markers, or improved skeletal muscle health. Metformin treatment, while exhibiting anti-neoplastic characteristics in many cancers, appears not to be an appropriate monotherapy for NSCLC tumor growth in vivo. Future studies should pursue co-treatment modalities, with metformin as a potentially supportive drug rather than a monotherapy to mitigate cancer progression.
format	article
author	Nicole L. Stott Bond Didier Dréau Ian Marriott Jeanette M. Bennett Michael J. Turner Susan T. Arthur Joseph S. Marino
author_facet	Nicole L. Stott Bond Didier Dréau Ian Marriott Jeanette M. Bennett Michael J. Turner Susan T. Arthur Joseph S. Marino
author_sort	Nicole L. Stott Bond
title	Low-Dose Metformin as a Monotherapy Does Not Reduce Non-Small-Cell Lung Cancer Tumor Burden in Mice
title_short	Low-Dose Metformin as a Monotherapy Does Not Reduce Non-Small-Cell Lung Cancer Tumor Burden in Mice
title_full	Low-Dose Metformin as a Monotherapy Does Not Reduce Non-Small-Cell Lung Cancer Tumor Burden in Mice
title_fullStr	Low-Dose Metformin as a Monotherapy Does Not Reduce Non-Small-Cell Lung Cancer Tumor Burden in Mice
title_full_unstemmed	Low-Dose Metformin as a Monotherapy Does Not Reduce Non-Small-Cell Lung Cancer Tumor Burden in Mice
title_sort	low-dose metformin as a monotherapy does not reduce non-small-cell lung cancer tumor burden in mice
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/5b63c08f901940bfac88d7f742fc1f04
work_keys_str_mv	AT nicolelstottbond lowdosemetforminasamonotherapydoesnotreducenonsmallcelllungcancertumorburdeninmice AT didierdreau lowdosemetforminasamonotherapydoesnotreducenonsmallcelllungcancertumorburdeninmice AT ianmarriott lowdosemetforminasamonotherapydoesnotreducenonsmallcelllungcancertumorburdeninmice AT jeanettembennett lowdosemetforminasamonotherapydoesnotreducenonsmallcelllungcancertumorburdeninmice AT michaeljturner lowdosemetforminasamonotherapydoesnotreducenonsmallcelllungcancertumorburdeninmice AT susantarthur lowdosemetforminasamonotherapydoesnotreducenonsmallcelllungcancertumorburdeninmice AT josephsmarino lowdosemetforminasamonotherapydoesnotreducenonsmallcelllungcancertumorburdeninmice
_version_	1718412898102935552

Low-Dose Metformin as a Monotherapy Does Not Reduce Non-Small-Cell Lung Cancer Tumor Burden in Mice

Ejemplares similares